Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

Abstract:

:Five patients from the Kyushu area in Japan with adult T-cell leukaemia (ATL) refractory to conventional chemotherapeutic agents were treated with 5 mg/m2 of the adenosine deaminase inhibitor, 2'-deoxycoformycin (DCF), intravenously (i.v.) for 3 consecutive days, followed by 5 mg/m2 i.v. weekly. Two patients showed a good response, and three were resistant to DCF. One patient with ATL receiving DCF had a continuous remission without further therapy. Another patient in the terminal stage received three daily injections of 7.5 mg of DCF. The most prominent change was the drop in the leucocyte count. The cell count fell from 116.4 X 10(9)/l to 2.0 X 10(9)/l on day 7. The only adverse effects of DCF therapy were gastrointestinal toxicity, nausea and vomiting. These results suggest that DCF may be a valuable drug for treating refractory ATL.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Yamaguchi K,Yul LS,Oda T,Maeda Y,Ishii M,Fujita K,Kagiyama S,Nagai K,Suzuki H,Takatsuki K

doi

10.1016/0145-2126(86)90251-1

subject

Has Abstract

pub_date

1986-01-01 00:00:00

pages

989-93

issue

8

eissn

0145-2126

issn

1873-5835

journal_volume

10

pub_type

杂志文章
  • The Brazilian Pediatric Myelodysplastic Cooperative Group strategies: are they relevant to improve educational approach and correct diagnosis?

    abstract::Brazil is a wide country with huge contrasts. Its peculiarities can highlight environmental factors that could influence the frequencies of different cancers. The standard treatment and results achieved from several different areas of the country may not be found in others. The establishment of a national cooperative ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(01)00187-4

    authors: Lopes LF,Lorand-Metze I,Niero-Melo L,Tone LG,Velloso E,Campanaro CM,Latorre Mdo R

    更新日期:2002-07-01 00:00:00

  • A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.

    abstract::We designed a pharmacokinetic and pharmacodynamic phase I study of sequential topotecan (2.55-6.3mg/m2) by 72h infusion followed by five daily doses of etoposide for patients with refractory acute leukemia based upon synergistic anti-tumor activity of topoisomerase I and II inhibitors in vitro. Eight of the 29 patient...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0145-2126(02)00079-6

    authors: Cooper BW,Donaher E,Lazarus HM,Green SB,Gosky DM,Rosenthal NS,Berger SJ,Li X,Ingalls ST,Hoppel CL,Gerson SL

    更新日期:2003-01-01 00:00:00

  • Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.

    abstract::The methylation inhibitor decitabine (DAC) has great therapeutic value for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, DAC monotherapy is associated with relatively low rates of overall response and complete remission. Previous studies have shown promising results for combination treatmen...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.02.002

    authors: Geng S,Yao H,Weng J,Tong J,Huang X,Wu P,Deng C,Li M,Lu Z,Du X

    更新日期:2016-05-01 00:00:00

  • Prototypical HTLV-I/II infection is rare in LGL leukemia.

    abstract::The etiology of LGL leukemia is not known; however, we recently detected HTLV-II in a patient with LGL leukemia. In this study, we found that sera from 6 of 28 patients with LGL leukemia were positive for HTLV-I/II using a whole virus ELISA; moreover, the ELISA-negative sera were near the positive cut-off value. There...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90078-7

    authors: Loughran TP Jr,Sherman MP,Ruscetti FW,Frey S,Coyle T,Montagna RA,Jones B,Starkebaum G,Poiesz BJ

    更新日期:1994-06-01 00:00:00

  • Malignant hematopoietic cell lines: in vitro models for the study of mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) is a distinct type of B cell malignancy and accounts for approximately 5-10% of non-Hodgkin's lymphomas (NHL). The characteristic cytogenetic aberration in MCL is the translocation (11;14)(q13;q32) present in virtually all cases. This rearrangement at the BCL1 locus at 11q13 dysregulates the...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00026-7

    authors: Drexler HG,MacLeod RA

    更新日期:2002-09-01 00:00:00

  • THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells.

    abstract::Normal human monocytes express Fas and are susceptible to Fas ligand (FasL)-induced apoptosis. Because the myeloid leukemia cell lines HL-60 and THP-1 can be differentiated into functional monocytes and macrophages, we studied their expression of Fas and Fas ligand (FasL) to determine whether there were differentiatio...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(99)00101-0

    authors: Bremner TA,Chatterjee D,Han Z,Tsan MF,Wyche JH

    更新日期:1999-10-01 00:00:00

  • Decreased blood flow to rat bone marrow, bone, spleen, and liver in acute leukemia.

    abstract::An acute promyelocytic leukemia in the rat (BNML) has been used in model studies on pathogenesis and therapy of human acute myeloid leukemia. The blood supply to bone marrow during BNML development has hitherto not been examined, even though in general, blood flow to hematopoietic tissues might affect drug treatment a...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90071-r

    authors: Iversen PO,Thing-Mortensen B,Nicolaysen G,Benestad HB

    更新日期:1993-08-01 00:00:00

  • A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.

    abstract::Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.12.008

    authors: Kim HP,Frankel AE,Hogge DE

    更新日期:2010-08-01 00:00:00

  • International Working Group on MDS cytogenetics: October 2007 meeting report.

    abstract::The inaugural meeting of the International Working Group on MDS cytogenetics convened 22-23 October 2007 in Chicago, IL. Under the sponsorship of the Myelodysplastic Syndromes Foundation, the group was organized to address the substantial need for worldwide standardized cytogenetic testing for MDS in clinical practice...

    journal_title:Leukemia research

    pub_type: 总体

    doi:10.1016/j.leukres.2008.03.009

    authors: Slovak ML,Dewald GW,International Working Group on MDS cytogenetics.

    更新日期:2008-09-01 00:00:00

  • Smoking as a contributing factor for development of polycythemia vera and related neoplasms.

    abstract::Smoking may be associated with accelerated erythropoiesis, leukocytosis and thrombocytosis, which are also hallmarks in patients with polycythemia vera, essential thrombocythemia and early stages of myelofibrosis (MPNs). The JAK-STAT and NF-κB signaling pathways are activated in both smokers and in patients with MPNs....

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2015.09.002

    authors: Hasselbalch HC

    更新日期:2015-09-09 00:00:00

  • Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.

    abstract::We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 year...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2009.08.010

    authors: Suzushima H,Wada N,Yamasaki H,Eto K,Shimomura T,Kugimiya MH,Horikawa K,Nishimura S,Tsuda H,Mitsuya H,Asou N

    更新日期:2010-05-01 00:00:00

  • XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.

    abstract::To further understand the role of XIAP in acute myeloid leukemia (AML), we suppressed XIAP expression by antisense oligonucleotides and determined the effect on gene expression profiles and biological pathways. XIAP inhibition upregulated expression of proteasome genes in a manner similar to the proteasome inhibitor b...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2013.04.018

    authors: Carter BZ,Mak DH,Wang Z,Ma W,Mak PY,Andreeff M,Davis RE

    更新日期:2013-08-01 00:00:00

  • Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.

    abstract::Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kinase and Rho GTPase. Upon activation by ROCK, LIM kinases (LIMK) inactiva...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2020.106490

    authors: Djamai H,Berrou J,Dupont M,Kaci A,Ehlert JE,Weber H,Baruchel A,Paublant F,Prudent R,Gardin C,Dombret H,Braun T

    更新日期:2020-12-13 00:00:00

  • Changes in the surface marker pattern related to maturation in adult acute myeloid leukaemia.

    abstract::Introduction of the maturation index (MI) as a measure for the degree of maturation improved the subtyping of acute myeloid leukemia (AML). A comparison is made here between the MI and the results of surface marker analysis with a panel of monoclonal antibodies (McAb) in the immunofluorescence technique. The McAb appl...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(83)90100-5

    authors: van Rhenen DJ,van der Reijden HJ,van't Veer MB,Engelfriet CP,von dem Borne AE,Langenhuijsen MM

    更新日期:1983-01-01 00:00:00

  • Neuroleukin mediated differentiation induction of myelogenous leukemia cells.

    abstract::Leukemia cells enriched from peripheral blood of a patient with myelogenous leukemia were induced to differentiate with a purified T cell lymphokine neuroleukin. With sufficient neuroleukin concentrations, cells with macrophage-like morphology were identified among the developing adherent cells. After 2-5 days, approx...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00129-5

    authors: Chiao JW,Xu W,Seiter K,Feldman E,Ahmed T

    更新日期:1999-01-01 00:00:00

  • Phorbol myristate acetate treatment of normal human myeloid blast cells promotes monopoiesis and inhibits granulopoiesis.

    abstract::Fractionation of mononuclear cells from human fetal liver provides a cell population at early stages of myeloid differentiation which, when cultured, generates neutrophils and macrophages for up to a month. These studies describe the further purification of an undifferentiated myeloid blast cell population by rosette ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(90)90114-o

    authors: Bunce CM,Patton WN,Pound JD,Lord JM,Brown G

    更新日期:1990-01-01 00:00:00

  • Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders.

    abstract::We investigated the expression of fos oncogene proteins in lymphoproliferative disorders, using a monoclonal antibody (FO-120) that was prepared against a synthetic oligopeptide of fos protein (amino acid sequence from 127 to 152). Although peripheral blood leukocytes were rarely positive for FO-120, they were transie...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(89)90010-6

    authors: Kanaitsuka T,Namba Y,Zu YL,Ishii K,Ashihara T,Hanaoka M,Suchi T

    更新日期:1989-01-01 00:00:00

  • Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.

    abstract::Although mutations in RNA splicing genes occur frequently in patients with clonal cytopenias of unknown significance (CCUS) and myelodysplastic syndromes (MDS), very often additional common myeloid gene driver mutations are present at diagnosis. Thus, the clinical significance of isolated mutations in the most commonl...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.09.002

    authors: Fleischman RA,Stockton SS,Cogle CR

    更新日期:2017-10-01 00:00:00

  • Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia.

    abstract::Overexpression of the Wilms' tumor gene 1 (WT1) was observed in most leukemia cells. In addition to four major isoforms of WT1, an N-terminally truncated isoforms (sWT1) has been identified. We separately quantified the transcript levels of sWT1 and full-length WT1 (fWT1) in 237 patients with acute myeloid leukemia (A...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.01.002

    authors: Ishikawa Y,Kiyoi H,Naoe T

    更新日期:2011-05-01 00:00:00

  • BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

    abstract::The Bcl-2 protein inhibits apoptosis (programmed cell death) of hematopoietic stem cells induced by a variety of noxious stimuli, thus mediating chemoresistance and decreasing chemosensitivity. Higher Bcl-2 expression correlates to an adverse outcome following therapy for acute myeloid leukemia (AML). The current stud...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.05.009

    authors: Moon JH,Sohn SK,Lee MH,Jang JH,Kim K,Jung CW,Kim DH

    更新日期:2010-02-01 00:00:00

  • Cytogenetic and DNA-flow cytometric studies of separated blasts.

    abstract::With Percoll density gradients, blasts from peripheral blood and bone marrow could be separated with a significant enrichment, and very often with a high degree of purity. This allowed a study of selected cases, where the separated sample exhibited chromosome abnormalities and/or an abnormal DNA content distribution (...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(85)90037-2

    authors: Berneman ZN,De Bock R,Van Alsenoy L,Vingerhoets W,Van den Bergh M,Dumon J,Peetermans M

    更新日期:1985-01-01 00:00:00

  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

    abstract::There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2020.106385

    authors: Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

    更新日期:2020-08-01 00:00:00

  • Pathogenesis of jumping translocations: a molecular cytogenetics study.

    abstract:BACKGROUND/AIMS:Jumping translocations are rare cytogenetic aberrations in haematological malignancies, the pathogenesis of which remains to be fully characterised. We investigated the mechanism of formation of jumping translocations in a case of adult common acute lymphoblastic leukaemia (ALL) positive for the Ph tran...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.01.021

    authors: Wan TS,Ma SK,Chow EY,Li YH,Lin SY,Chan LC

    更新日期:2004-10-01 00:00:00

  • Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells.

    abstract::Osteogenic growth peptide (OGP) is a peptide exerting regulatory effects on the bone and on bone marrow. The carboxy-terminal pentapeptide (OGP10-14) is the biologically active portion of OGP. We evaluated OGP10-14 hematopoietic activity performing colony-forming tests on human stem cells derived by bone marrow, perip...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00008-5

    authors: Fazzi R,Galimberti S,Testi R,Pacini S,Trasciatti S,Rosini S,Petrini M

    更新日期:2002-09-01 00:00:00

  • Flow cytometric assessment of three different methods for the measurement of in vitro apoptosis.

    abstract::Chlorambucil-induced apoptosis was assessed by three different flow cytometric methods in B-cell chronic lymphocytic leukaemia (B-CLL) cells cultured in vitro and the results were compared with those derived from the morphological assessment of the same samples. Spontaneous apoptosis was consistently observed in the c...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00013-7

    authors: Pepper C,Thomas A,Tucker H,Hoy T,Bentley P

    更新日期:1998-05-01 00:00:00

  • Hyaluronan induces migration of multidrug-resistant lymphoma cell lines in vitro through Tiam1 activation by a PI3K-dependent mechanism.

    abstract::Hyaluronan (HA) modulates multidrug resistance (MDR) as well as cell migration. Tiam1 is involved in cytoskeleton reorganization during tumor invasion. In this report we show the relationship among HA, Tiam1, migration and MDR in murine lymphoma cell lines. We observed that MDR cells presented higher migratory capacit...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.02.020

    authors: Cordo-Russo RI,Alaniz LD,Saccodossi N,Lompardía S,Blanco G,Alvarez E,García MG,Hajos SE

    更新日期:2010-11-01 00:00:00

  • Expression of IL-18 and its receptor in human leukemia cells.

    abstract::The importance of IL-18, although clearly established in solid tumors, has not been fully elucidated in human hematopoietic neoplasms. Here we examined the mRNA and protein for IL-18 in eight human hematopoietic cell lines representing different lineages and neoplasms including leukemia, lymphoma and others. Our resul...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(03)00005-5

    authors: Zhang B,Ma XT,Zheng GG,Li G,Rao Q,Wu KF

    更新日期:2003-09-01 00:00:00

  • Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia.

    abstract::A 53-year-old male patient was admitted to our hospital with painful splenomegaly. He was diagnosed as having chronic myelomonocytic leukemia (CMML) with leukocytosis, monocytosis, increased lysozyme concentrations in serum und urine, and lack of the Philadelphia chromosome. The clinical course of the disease was char...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(96)00117-8

    authors: Aul C,Gattermann N,Germing U,Südhoff T,Hollmig KA,Heyll A

    更新日期:1997-03-01 00:00:00

  • Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.

    abstract::We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six pa...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.12.001

    authors: Scholl S,Loncarevic IF,Krause C,Kunert C,Clement JH,Höffken K

    更新日期:2005-07-01 00:00:00

  • Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS).

    abstract::We have previously reported that serum stem factor (SCF) levels are significantly lower in patients with myelodysplastic syndrome (MDS) than normal controls. We have now studied the effects of adding SCF to cultures of blood mononuclear cells from patients with MDS and normal subjects. Three of 17 patients with MDS sh...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(95)00034-l

    authors: Masters GS,Baines P,Tang C,Bowen D,Burnett AK

    更新日期:1995-08-01 00:00:00